Literature DB >> 10050702

Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.

L Bara1, A Planes, M M Samama.   

Abstract

Studies in experimental animal models and in patients receiving low molecular weight heparin (LMWH) to prevent thromboembolic events after surgery have not demonstrated a clear relationship between anti-Xa and anti-IIa activities in plasma and either bleeding or prevention of thrombosis. The relationship between these clinical outcomes and ex vivo anti-Xa and anti-IIa activities, activated partial thromboplastin time (APTT) and D-dimers were evaluated in 440 patients undergoing total hip replacement and given prophylaxis once daily with a LMWH (tinzaparin or enoxaparin) in a multicentre double-blind randomized study. 221 patients received 4500 anti-Xa IU of tinzaparin; 219 patients received 40 mg (4000 anti-Xa IU) of enoxaparin. Both regimens were administered subcutaneously once daily. Blood samples for anti-IIa, anti-Xa, D-dimers levels and APTT were taken at baseline, on day 1, day 5 and on the day of discharge (days 8-14) and clinical assessments were performed dafly until day 14. All patients had bilateral venography between days 8 and 14. All coagulation tests were performed in central laboratories. A significant correlation was observed between anti-IIa activity and anti-Xa activity and the dose of each LMWH injected. The anti-Xa activity was significantly higher with enoxaparin and the anti-IIa activity was significantly higher with tinzaparin. No clear relationship between these two activities and the clinical outcomes was observed. This was also true with regards to APTT. Before and after surgery, D-dimers were significantly higher in patients with deep vein thrombosis (DVT) than in those without DVT but had no predictive value. Interestingly, a significant post-operative increase of D-dimers persisted in both groups of patients during the whole observation period, possibly suggesting that a longer duration of prophylactic treatment may be appropriate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10050702     DOI: 10.1046/j.1365-2141.1999.01153.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

1.  Effect of oral administration of unfractionated heparin (UFH) on coagulation parameters in plasma and levels of urine and fecal heparin in dogs.

Authors:  Malathi Erickson; Linda M Hiebert; Anthony P Carr; Jocelyn D Stickney
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Coagulation Day 2010: an Austrian survey on the routine of thromboprophylaxis in intensive care.

Authors:  E Schaden; P G Metnitz; G Pfanner; S Heil; T Pernerstorfer; P Perger; H Schoechl; D Fries; M Guetl; S Kozek-Langenecker
Journal:  Intensive Care Med       Date:  2012-03-24       Impact factor: 17.440

Review 3.  Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.

Authors:  Sheridan M Hoy; Lesley J Scott; Greg L Plosker
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

4.  Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.

Authors:  Philippe Cestac; Haleh Bagheri; Maryse Lapeyre-Mestre; Pierre Sié; Atoussa Fouladi; Eric Maupas; Philippe Léger; Bernard Fontan; Patrice Massip; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.

Authors:  Jeremy W Vandiver; Leticia I Ritz; Jeffrey T Lalama
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

6.  Renal function and thromboprophylaxis in critically ill patients.

Authors:  Gareth M Scholey; Anton G Saayman; Christopher D Hingston; Matt P Wise
Journal:  Crit Care       Date:  2010-05-12       Impact factor: 9.097

Review 7.  Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review.

Authors:  Gregory Egan; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2015 Jan-Feb

8.  Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial.

Authors:  Sian Robinson; Aleksander Zincuk; Thomas Strøm; Torben Bjerregaard Larsen; Bjarne Rasmussen; Palle Toft
Journal:  Crit Care       Date:  2010-03-18       Impact factor: 9.097

9.  Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin.

Authors:  B Dufour; M Toussaint-Hacquard; A Kearney-Schwartz; M D P Manckoundia; M C Laurain; L Joly; J Deibener; D Wahl; T Lecompte; A Benetos; C Perret-Guillaume
Journal:  J Nutr Health Aging       Date:  2012-07       Impact factor: 4.075

Review 10.  Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors:  Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.